Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of AbbVie Inc. NYSE: ABBV. In a filing disclosed on March 19th, the Representative disclosed that they had bought between $1,001 and $15,000 in AbbVie stock on March 17th.
Representative Marjorie Taylor Greene also recently made the following trade(s):
- Purchased $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOG on 3/17/2025.
- Purchased $1,001 - $15,000 in shares of Cardinal Health NYSE: CAH on 3/17/2025.
- Purchased $1,001 - $15,000 in shares of Apple NASDAQ: AAPL on 3/17/2025.
- Purchased $1,001 - $15,000 in shares of Kinder Morgan NYSE: KMI on 3/17/2025.
- Purchased $1,001 - $15,000 in shares of Digital Realty Trust NYSE: DLR on 3/17/2025.
- Purchased $1,001 - $15,000 in shares of Caterpillar NYSE: CAT on 3/17/2025.
- Purchased $1,001 - $15,000 in shares of Blackstone NYSE: BX on 3/17/2025.
- Purchased $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 3/17/2025.
- Purchased $1,001 - $15,000 in shares of United Parcel Service NYSE: UPS on 3/17/2025.
- Purchased $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 3/17/2025.
AbbVie Trading Down 0.4 %
NYSE ABBV traded down $0.76 during mid-day trading on Monday, reaching $209.25. 7,393,005 shares of the stock were exchanged, compared to its average volume of 5,252,783. The stock has a market cap of $369.40 billion, a P/E ratio of 87.19, a P/E/G ratio of 1.62 and a beta of 0.61. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.55. AbbVie Inc. has a one year low of $153.58 and a one year high of $218.66. The stock has a 50 day simple moving average of $194.49 and a 200-day simple moving average of $188.61.
AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Friday, January 31st. The company reported $2.16 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a return on equity of 296.28% and a net margin of 7.59%. During the same period in the prior year, the business earned $2.79 earnings per share. On average, analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.
AbbVie Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be given a dividend of $1.64 per share. This represents a $6.56 annualized dividend and a dividend yield of 3.14%. The ex-dividend date of this dividend is Tuesday, April 15th. AbbVie's dividend payout ratio (DPR) is presently 273.33%.
Institutional Trading of AbbVie
Several institutional investors and hedge funds have recently bought and sold shares of ABBV. M1 Capital Management LLC bought a new position in AbbVie in the 4th quarter worth about $229,000. DSG Capital Advisors LLC bought a new position in shares of AbbVie in the fourth quarter worth approximately $3,213,000. Chancellor Financial Group WB LP purchased a new stake in AbbVie in the fourth quarter valued at approximately $981,000. Thoma Capital Management LLC bought a new stake in AbbVie during the fourth quarter valued at approximately $551,000. Finally, Lansforsakringar Fondforvaltning AB publ purchased a new position in AbbVie in the 4th quarter worth approximately $104,347,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.
Insider Transactions at AbbVie
In other AbbVie news, EVP Perry C. Siatis sold 5,778 shares of AbbVie stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $197.90, for a total transaction of $1,143,466.20. Following the transaction, the executive vice president now directly owns 22,381 shares of the company's stock, valued at approximately $4,429,199.90. This trade represents a 20.52 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Timothy J. Richmond sold 29,917 shares of the company's stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $202.90, for a total transaction of $6,070,159.30. Following the completion of the sale, the executive vice president now directly owns 44,284 shares of the company's stock, valued at $8,985,223.60. This trade represents a 40.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 54,639 shares of company stock valued at $11,067,025 in the last quarter. Insiders own 0.25% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities research analysts have commented on ABBV shares. Guggenheim raised their price target on shares of AbbVie from $212.00 to $214.00 and gave the stock a "buy" rating in a report on Monday, February 3rd. Erste Group Bank upgraded AbbVie to a "strong-buy" rating in a research note on Monday, March 17th. Wells Fargo & Company upped their price target on AbbVie from $210.00 to $240.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Morgan Stanley raised their price objective on AbbVie from $224.00 to $239.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. Finally, Truist Financial upped their target price on AbbVie from $211.00 to $217.00 and gave the stock a "buy" rating in a research report on Monday, February 3rd. Five research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $211.45.
Read Our Latest Report on AbbVie
About Representative Greene
Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia's 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.
Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia's 14th Congressional District. She declared candidacy for the 2026 election.
About AbbVie
(
Get Free Report)
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Featured Articles
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
